September 24th, Switzerland

Free Registration, Part of MipTec 2014, Congress Center Basel

Friday, September 19, 2014

SCHEDULE UPDATE: SEPTEMBER 19TH

PLEASE UPDATE YOUR SCHEDULES



Meeting Location:
Congress Center Basel, MipTec Conference, Scientific Forums

Room 2
Day 1: Tuesday, September 23, 2014, Room 2
08:45-09:00
Introduction to Forum and Day 1

Forum chairs: Alex Zhavoronkov, PhD, Bhupinder Bhullar, PhD
Keynotes and Hallmarks of Aging Research
09:00 - 09:20
Advances in aging biomarkers and drugs with geroprotective properties

Brian Kennedy PhD, Director, CEO, Buck Institute for Aging Research
09:20 - 09:40
New approaches in aging diagnostics

Charles Cantor PhD, Professor, Boston University
09:40 - 10:00
The example of the discovery and development of of mitochondrial derived peptides to delay aging

Nir Barzilai, Director, Albert Einstein College of Medicine
10:00-10.20
Effects of mTOR Inhibition on Immunosenescence  in Elderly Humans

Joan Mannick, MD, Director, Translational Medicine, Novartis Institute for Biomedical Research
10:20-10:40
Break
Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design
Session Chair: Joao Pedro Megalhaes, PhD
10:40 - 11:00
Novel methods for selecting targeted drugs for personalized medicine in oncology

Anton Buzdin, PhD, DSc, President, CEO, Pathway Pharmaceuticals, Hong Kong
11:00 - 11:20
Bioinformatic analysis of the “omics” data from long-lived animals for geroprotector discovery

Joao Pedro De Magalhaes, PhD, Lab Head, University of Liverpool
11:20 - 11:40
In silico screening for novel drugs with geroprotective properties

Alexander Zhavoronkov, PhD, Director, The Biogerontology Research Foundation, CEO, Insilico Medicine, Inc
11:40 - 12:00
Using novel isotopically-fortified organic compounds to slow down aging processes and treat aging-related diseases

Charles Cator, PhD (on behalf of Robert Molinari, PhD, CEO, Retrotope, Inc)
12:00 -13:30
Lunch and Industry symposia
Room 5
Keynote address: R&D productivity: revival or further decline?
13:30 - 14:15
Dr. Joerg Reinhardt, Chairman of the Board of Directors, Novartis


Session II: Drugs with the potential geroprotective properties
Session Chair: Alexey Moskalev, PhD, DSc
14:30-14:40
Introduction to Session II

Bhupinder Bhullar, PhD
14:40 - 15:00
Advances in the Advanced Glycation Endproduct (AGE) breakers

William Bains, PhD, Head of the SENS Laboratory, Cambridge
15:00 - 15:20
Overview of the possible geroprotectors

Sven Bulterijs, PhD, Post-grad researcher, Yale University
15:20 - 15:40
Applied Epigenetics of Aging and Longevity

Olga Kovalchuk, PhD, Professor, Lab Head, University of Lethbridge, Director, Canada Cancer and Aging Research Laboratories
15:40-16:00
Break
16:00 - 17:00
Roundtable Discussion: How can Pharma engage in aging research?

Moderator: Alex Zhavoronkov, PhD


Day 2: Wednesday, September 24, 2014
08:45 - 09:00
Introduction to Forum and Day 2

Forum Chairs: Alex Zhavoronkov, PhD, Bhupinder Bhullar, PhD
Keynotes and Hallmarks of Aging Research
09:00 - 09:20
Rapamycin and other geroprotectors

Mikhail Blagosklonny, MD, PhD, Professor, Editor-in-Chief of Aging, Cell Cylcle and Oncotarget high-impact journals, Rosewell Park, NY
09:20 - 09:40
The role of Indy in fly health and longevity

Blanka Rogina, PhD, Director Genetics & Developmental Biology Graduate Program, University of Connecticut
09:40 - 10:00
Translating Advances from the Basic Biology of Aging into Clinical Application: Opportunities and Challenges

James Kirkland, MD, PhD, Professor, Mayo Clinic
10:00 - 10:20
How to Solve Genetic Disease on a Population Scale

Barry Merriman, PhD, Professor, UCLA / Lead System Architect, CSO, Thermo Fisher Scientific
10:20 - 10:40
Coffee Break
Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy
Session Chair: Alexander Bürkle, PhD
10:40 - 11:00
Lessons learned from the EU FP7 MARKAGE Project

Alexander Bürkle, PhD, Professor, EU MARK-AGE Co-ordinator, University of Konstanz
11:00 - 11:20
Comparative genomics of aging and longevity

Vadim Gladyshev, PhD, Professor, Department of Medicine, Harvard Medical School, Director of Redox Medicine, Medicine, Brigham And Women's Hospital, Harvard
11:20 - 11:40
Gene expression patterns in progeria, age-related macular degeneration (AMD) and other age-related diseases

Antonei Benjamin Csoka, PhD, Assoc. Professor, Howard University, CEO, Vision Genomics, Inc
11:40 - 12:00
Experimental approaches to screening of aging-suppressive drugs

Alexey Moskalev, PhD, DSc, Professor, head of the laboratory Moscow Institute of Physics and Technology
12:00 - 13:30
Lunch and Industry Symposia
Room 5
Keynote Address: TBD
13:30 - 14:15
 Dr. Patrick Aebischer,  President Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
Session IV: Trends in Aging Research for Drug Discovery
Session Chair: Richard Faragher, PhD
14.30 - 15:00
Pharmacological prospects for health span extension

Richard Faragher, Professor, University of Brighton
15:00-15:30
Ageing Research and Regenerative Medicine Industry Outlook

Geoffrey Furlonger, CEO, Aging Analytics, Charles Groome, Head of Communications, Aging Analytics UK
15:30 - 16:00
Big Data in Biomedicine: Applying machine learning to predict the outcomes of biomedical research projects

Dmitry Kaminskiy, Director, Senior Partner, Deep Knowledge Ventures
16:00 - 16:20
Coffee Break
16:20 - 16:40
Trends in aging research policy: past, present and future

Dan Perry, CEO, Alliance for Aging Research, USA
16:40-17:00
Concluding remarks and follow up publications

Bhupinder Bhullar, PhD, Director, Novartis; Alex Zhavoronkov, PhD, CEO, Insilico Medicine, Inc

0 comments:

Post a Comment

Note: Only a member of this blog may post a comment.